Pharmacy Benefits Management

January 14, 2022
Rinvoq-Receives-New-Atopic-Dermatitis-Indication

Rinvoq Receives New Atopic Dermatitis Indication

January 14, 2022 – AbbVie's Rinvoq® (upadacitinib) has been approved to treat moderate to severe atopic dermatitis (AD) in patients at least 12 years old who have refractory disease
January 14, 2022
Cibinqo-Approved-to-Treat-Atopic-Dermatitis

Cibinqo Approved to Treat Atopic Dermatitis

January 14, 2022 – The U.S. FDA has approved Cibinqo® (abrocitinib) to treat moderate to severe atopic dermatitis in adults who have refractory disease not adequately controlled with other
January 13, 2022
Ryaltris-Nasal-Spray-Approved-for-Allergic-Rhinitis

Ryaltris Nasal Spray Approved for Allergic Rhinitis

January 13, 2022 – RyaltrisTM (olopatadine hydrochloride/mometasone furoate monohydrate) nasal spray has been FDA approved to treat the symptoms of seasonal allergic rhinitis in patients